


# Propelling New Treatments for Healthier Futures




## CureSearch Mission


Our mission is to end children's cancer by driving targeted and innovative research with measurable results in an accelerated time frame.

## CureSearch Vision

Advance better, less-toxic treatments to ensure all children with cancer live long, healthy lives.



## Message from the CEO



For every child and family struggling with a cancer diagnosis, hope is their greatest ally, especially during the most difficult times. At CureSearch, we fight for that hope every day—the hope that every child will live cancer free.

**In 2018, we will continue to fund high-potential children's cancer research while driving real patient impact.** Our Catapult Awards will fund clinic-ready Phase 1 and Phase 2 pediatric cancer clinical trials and with the help of our best-in-class advisory councils, we are excited to announce the results this spring. Our Catapult Request for Application (RFA) received 16 strong letters of intent that are currently under review.

CureSearch is leading the way to develop less-toxic treatments and cures through our Catapult Strategy. Catapult continues to foster imperative collaborations between industry leaders and accelerate better treatments, because we believe every child with cancer deserves a healthier future.

None of this would be possible without people like you. Thank you for your heartfelt support of the CureSearch mission.

Sincerely,

Laura Thrall

CEO, CureSearch for Children's Cancer

## Our Impact

### New Treatments for Healthier Futures

CureSearch continues to drive innovative, patient-centered research for children's cancer. We're accomplishing this by supporting research programs that are laser focused on accelerating treatments with results. Our impact is measured by the advancements in children's cancer research and treatments that are propelled to market. See our impact by the numbers:

As of December 2017

25


new drugs in  
preclinical testing for:



- ✓ high-risk brain cancer
- ✓ sarcoma
- ✓ leukemia
- ✓ Wilms tumor

300+


potential new  
drug targets



being studied for 9 types  
of children's cancer

1

investigational  
new drug (IND)  
application



submitted to Food & Drug  
Administration (FDA)

1

novel drug for Ewing sarcoma



nearing pediatric clinical trials

3

clinical trials



for adolescent/young adult transition

### Total Grants Awarded

18

Young  
Investigator  
Awards

6


Acceleration  
Initiative  
Awards

40

Community  
Impact  
Awards

See Our Impact

## Researcher Highlight



Richard Gilbertson, MD, PhD

Acceleration Initiative Investigator

University of Cambridge  
*Targeted Therapies for High-Risk  
Brain Tumors*

“ I have been working on children's brain tumors for 30 years. It began as a medical student working on a small research project on medulloblastoma. I have worked on it ever since. I was drawn to the disease by the courage of the children and families facing the disease and the great need to improve understanding and outcomes of these tumors. ”

## Catapult Strategy Update


### Bringing New Treatments to Market

Through the Catapult Research Strategy, we actively address the barriers that prevent safer treatments from reaching the children who need it most. We are helping children's cancer research reach its full potential by catapulting research past the “Valley of Death,” a place where great research falls short of making it to clinical trials.



CURESEARCH  
CATAPULT

### STRATEGY



Learn More About Catapult

## Program Updates

### Young Investigators

The Young Investigators program provides critical funding for early discovery-stage researchers to keep promising pediatric cancer research moving forward while arming industry leaders with the tools to pursue drug development.


Since 2012, CureSearch has invested \$2.55M in the Young Investigator Program, funding 18 awards leading to new discoveries and potential new treatments for kids.

“ I am very proud of the work we have done with the support of CureSearch in building the research and analysis pipeline to use single-cell studies for childhood leukemia with a true translational endpoint. This work has been a labor of love. ”

Dr. Kara Davis,  
Young Investigator,  
Sponsored by Love Your Melon

love  
YOUR  
melon

### Young Investigator Cumulative Impacts



### Young Investigator Program in Drug Development

CureSearch continues to support and educate Young Investigators in pediatric cancer drug development; CureSearch launched a Request for Applications (RFA) that resulted in:

19 outstanding  
letter of intent applications  
for 2018 grants

6 full applications  
were reviewed

\*Awardees will be announced in March 2018.

Learn More

## Acceleration Initiative

The \$10M Acceleration Initiative invests in the best, most innovative pediatric cancer research. We bring together the brightest thought leaders in the field today to overcome the greatest challenges in children's cancer research.

### Acceleration Initiative Cumulative Impacts



Learn More



## Catapult Awards

### Supporting Promising Therapies for Pediatric Cancer

CureSearch Catapult Awards push forward promising therapies that show a strong potential for future approval and commercialization. The ultimate goal is to improve clinical outcomes and make new treatments widely available for childhood cancer patients.

Read more about our Catapult Awards RFAs:

#### ● Catapult General RFA

Launched in October 2017, we solicited high-potential clinic ready projects aiming to test novel or repurposed targeted therapies for pediatric cancer in Phase 1 or Phase 2 clinical trials. Proposals are currently under review. The first Catapult Award will be selected in March 2018.

#### ● Immunotherapy RFA

Initiated in partnership with the Parker Institute for Cancer Immunotherapy, the project will co-fund high-potential immuno-oncology clinical trials for pediatric cancer. More details about this exciting RFA will be released in spring 2018.


#### ● Molecular Targets RFA

In fall 2018, we will open a RFA to advance drug development and clinical trials for key, high-priority molecular targets.



In fall 2017, CureSearch and the Parker Institute for Cancer Immunotherapy announced a collaboration in which each entity will contribute funding, resources and infrastructure to support children's cancer research. Together, we will seek out strong immunotherapy projects that are bold and disruptive to make the biggest impact on the treatment of children's cancer.

[Learn More](#)



Your voice matters. To share your thoughts on how we can serve the research community, fill out this three-minute survey.

[Take the Survey Now](#)

## CureSearch Brain Trust—Our Councils\*

CureSearch's councils are made up of leading clinicians, scientists, industry experts and business leaders that inform our research strategy by providing objective expertise and thought leadership. They help select the very best research that is most likely to make it to the marketplace in an accelerated time frame:

#### Scientific Advisory Council


Sets the academic priorities for Catapult and evaluates projects on scientific merit.



**Led by**  
**Richard O'Reilly, MD**  
Memorial Sloan Kettering Cancer Center

#### Industry Advisory Council


Champions pediatric cancer within industry, evaluates projects on likelihood of development, and provides industry expertise to Catapult researchers.



**Led by**  
**Raphaël Rousseau, MD, PhD**  
Grifstone Oncology

#### Scientific Review Committee

Provides rigorous peer review of research proposals, evaluating: scientific merits, innovation, unmet need and clinical impacts.



**Led by**  
**Stephen Sallan, MD**  
Dana-Farber Cancer Institute

#### Catapult Advisory Council

Supports the development and operation of the Catapult Impact Fund.



**Led by**  
**Kathy Wanner**  
Abundant Venture Partners

\*Council chair leadership may vary after May 2018 as terms come to an end.

[Meet Our Council Members](#)

## Enhanced Resources

CureSearch not only focuses on an impactful research strategy, but also provides families with the tools and resources they need to understand their cancer diagnosis and treatment options. We are proud to debut a new educational video and eBook on immunotherapy, one that families can view together.



To view this video, eBook and other resources, visit [curesearch.org/immunotherapy-resources](http://curesearch.org/immunotherapy-resources)

Generously sponsored by:



## 2017 Fundraising Events

#### CURESEARCH SUPERHEROES UNITE!

Held  
**16 events**

Raised more than  
**\$846,000**

#### CURESEARCH ULTIMATE HIKE

Held  
**6 events**

Raised more than  
**\$742,000**

#### CURESEARCH GOLD

Held  
**40 events**

Raised more than  
**\$230,000**

#### CURESEARCH CHALLENGE

**63 participants**


Raised more than  
**\$34,000**

CureSearch was proud to have cancer survivor **Beau Swallow** represent CureSearch and our mission at the 2017 QBE Shootout.

QBE Shootout was made up of 24 PGA Tour golf pros and 300 volunteers with one goal—to raise critical funds for CureSearch's mission. Beau spoke at the annual Pro-Am Awards Dinner that highlights tournament week and talked about his resilience in fighting and eliminating Stage IV Ewing sarcoma that had spread to his chest and lungs in 2009. After several surgeries, 23 rounds of chemotherapy and radiation, Beau is fully in remission and a student at American University.

A very special thanks to the Wasserman Group and Greg Norman for their support.

[Learn More](#)



Beau pictured with legendary golfer Greg Norman

We are grateful to the families who have established a Champion or Legacy Fund to honor their child:

- Jacob Koenigs 'Jakefest' Memorial Fund and Kiewit
- Luke McGuire Legacy Fund
- Joey Keller Legacy Fund
- Hammond Family Fund
- Nick Currey Fund
- Eloise Dodge Gould Legacy Fund
- Amy Miller Champion Fund
- Dean & Diane Schafer: In Memory of Madison Star Schafer

We are honored that the following individuals have become members of the Legacy Society by including CureSearch in their will or trust:

The Howard and Janet Emery Living Trust

Jean B. Michael


Robert T. Ridley

[Establish a Champion or Legacy Fund](#)

## Our Generous Partners

Our work would not be possible without the extraordinary support of the following partners, including their generous employees and customers:

#### Catapult Partners




#### Research Grant Partners

Mathile Family Foundation  
Corn Endowment (Georgia Regents University)

#### Co-funding Partners

Parker Institute for Cancer Immunotherapy  
Alan B. Slifka Foundation  
Rising Tide For Clinical Cancer Research

#### Corporate Partners



For more information, please contact:

Sarita Sastry, PhD  
National Director, Research and Programs  
[sarita.sastry@curesearch.org](mailto:sarita.sastry@curesearch.org)

Kay Koehler  
Chief Development Officer  
[kay.koehler@curesearch.org](mailto:kay.koehler@curesearch.org)



CURESEARCH  
FOR CHILDREN'S CANCER

CureSearch for Children's Cancer  
4600 East-West Highway, Suite 600  
Bethesda, MD 20814

[www.curesearch.org](http://www.curesearch.org)  
(800) 458-6223

